These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 6773844)
1. Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2'-tetrahydrofuryl)-5-fluorouracil. Kimura K; Suga S; Shimaji T; Kitamura M; Kubo K; Suzuoki Y; Isobe K Gastroenterol Jpn; 1980; 15(4):324-9. PubMed ID: 6773844 [TBL] [Abstract][Full Text] [Related]
2. Anticancer drug distribution in lymph and blood during adjuvant chemotherapy after surgery for gastric carcinoma. A study with a combined preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil. Hanaue H; Kurosawa T; Kitano Y; Miyakawa S; Nemoto A; Yamamoto H; Asagoe T; Takada T; Yasuda H; Shikata J Cancer; 1987 May; 59(9):1571-6. PubMed ID: 3103905 [TBL] [Abstract][Full Text] [Related]
3. Uracil-tegafur in gastric carcinoma: a comprehensive review. Takiuchi H; Ajani JA J Clin Oncol; 1998 Aug; 16(8):2877-85. PubMed ID: 9704742 [TBL] [Abstract][Full Text] [Related]
4. [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT]. Inaba S; Kondo Y; Tsuchiya K; Kawai K; Ogino A; Umeda T; Ueda Y Gan To Kagaku Ryoho; 1992 Nov; 19(13):2175-80. PubMed ID: 1444483 [TBL] [Abstract][Full Text] [Related]
5. [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT]. Takahashi N; Nitta A; Saitou T; Mori Y; Kunii Y; Kikuchi K Gan To Kagaku Ryoho; 1988 Aug; 15(8):2319-23. PubMed ID: 3136701 [TBL] [Abstract][Full Text] [Related]
6. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Hoff PM; Pazdur R; Benner SE; Canetta R Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients]. Kamiya O; Hoshino A; Ohara K; Nagata K; Kojima T; Sugihara T; Yamada M; Suzuki M; Kimura K; Fujii S Gan To Kagaku Ryoho; 1983 Dec; 10(12):2565-72. PubMed ID: 6418079 [TBL] [Abstract][Full Text] [Related]
8. Scientific basis for the combination of tegafur with uracil. Maehara Y; Kakeji Y; Ohno S; Baba H; Sugimachi K Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):14-21. PubMed ID: 9348561 [TBL] [Abstract][Full Text] [Related]
9. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats. Kawaguchi Y; Nagayama S; Masuda H; Yasuda A Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982 [TBL] [Abstract][Full Text] [Related]
10. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123 [TBL] [Abstract][Full Text] [Related]
11. [5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur]. Arima S; Futami K; Shigeta M; Kinashi M; Shimura H Gan To Kagaku Ryoho; 1986 Aug; 13(8):2618-24. PubMed ID: 3090940 [TBL] [Abstract][Full Text] [Related]
12. [Blood levels of 5-FU and uracil on additional use of uracil in UFT therapy in gastrectomized patients]. Suda Y; Uchida K Gan To Kagaku Ryoho; 1995 Sep; 22(10):1343-7. PubMed ID: 7668868 [TBL] [Abstract][Full Text] [Related]
13. [5-FU concentration in blood and tissue of patients with renal cell carcinoma after administration of UFT]. Masuda F; Suzuki M; Ohnishi T; Nakada J; Mori Y; Iizuka N; Machida T Gan To Kagaku Ryoho; 1985 Feb; 12(2):320-4. PubMed ID: 3918507 [TBL] [Abstract][Full Text] [Related]
14. [Blood and tumor levels of tegafur, 5-fluorouracil, and uracil]. Takeshita T; Iwasaki M; Narita M; Sou M; Sato M; Hashimoto T; Kameya S; Iigima N Gan To Kagaku Ryoho; 1988 Nov; 15(11):3053-8. PubMed ID: 3142365 [TBL] [Abstract][Full Text] [Related]
15. Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine. Ooi A; Ohkubo T; Higashigawa M; Kawasaki H; Kakito H; Kagawa Y; Kojima M; Sakurai M Biol Pharm Bull; 2001 Nov; 24(11):1329-31. PubMed ID: 11725974 [TBL] [Abstract][Full Text] [Related]
16. [5-FU concentration in tissues of gastric cancer patients with preoperative administration of UFT--especially in comparison with FT-207]. Takeshita M; Ishikawa H; Seki M; Ikeya T; Miyamoto Y; Izuo M; Tozuka S; Usui R; Kaneko H Gan No Rinsho; 1985 Oct; 31(13):1697-703. PubMed ID: 3935831 [TBL] [Abstract][Full Text] [Related]
17. [Level of 5-FU in tumor tissues of the patients with head and neck malignant tumors after oral administration of UFT]. Kusama M; Utsunomiya Y; Ono T; Nagura H; Enomoto S Gan To Kagaku Ryoho; 1983 Aug; 10(8):1796-802. PubMed ID: 6411004 [TBL] [Abstract][Full Text] [Related]
18. [Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT]. Suemasu K; Nomoto C; Higashi Y Gan To Kagaku Ryoho; 1982 Apr; 9(4):667-71. PubMed ID: 6820904 [TBL] [Abstract][Full Text] [Related]
19. Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study. Li W; Zhao X; Wang H; Liu X; Zhao X; Huang M; Qiu L; Zhang W; Chen Z; Guo W; Li J; Zhu X Oncotarget; 2017 Jun; 8(23):37826-37834. PubMed ID: 27980221 [TBL] [Abstract][Full Text] [Related]
20. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Fujii S; Kitano S; Ikenaka K; Shirasaka T Gan; 1979 Apr; 70(2):209-14. PubMed ID: 381088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]